Norway's ArcticZymes Q2 revenue rises 19%, EBITDA up 90%
Norway's ArcticZymes Q2 revenue rises 19%, EBITDA up 90%
Overview
Norway enzyme maker's Q2 revenue rose 19% yr/yr to NOK 31.9 mln
EBITDA increased 90% yr/yr to NOK 7.4 mln, margin improved to 23% from 15%
Molecular Tools segment led growth; Biomanufacturing declined vs record Q2 2025 but up sequentially
Outlook
Company aims for sustainable double-digit growth in the second half of 2026
Company sees potential growth from US customer’s FDA-approved cancer screening test, but timing uncertain
Result Drivers
MOLECULAR TOOLS GROWTH - Segment revenue rose 84% yr/yr, driven by return of key OEM account and broad customer demand
OPERATING LEVERAGE - Sales growth outpaced cost increases, allowing most incremental revenue to flow through to EBITDA
BIOMANUFACTURING PHASING - Segment declined yr/yr vs record Q2 2025, but grew 6% sequentially; adoption among CDMOs continued through the quarter
Company press release: ID:nWkrJspz7
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| NOK 31.90 mln |
|
Q2 EBITDA |
| NOK 7.40 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 44 three months ago
Reuters Recommended Reads
Aug 11 - Codexis Q2 net loss narrows, helped by lower operating expenses
Aug 14 - Germany's Stratec H1 revenue falls on service parts, consumables segment decline
Aug 12 - Bio-Techne Q4 revenue rises 3%, beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)